Company: GenSight Biologics
Job title: Director - Analytical Development & Nonclinical Research
Dr Pierre Burguière is Director – Analytical Development and Nonclinical Research at GenSight Biologics in Paris (France), an innovative clinical-stage gene therapy company focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. Prior to that he worked for 10 years (2007-2017) in the field of beneficial microbes within leader companies (Europe and North America) where he held different positions such as Global Quality Director, Preclinical Research Director and Research Scientist. Dr Burguière earned a PhD in Microbiology & Molecular Biology from University Paris Diderot, during which he researched on Bacillus subtilis sulfur metabolism and its regulation at the Institut Pasteur in Paris. Dr Burguière’s main fields of expertise are research programs & budget management, team management, bioanalytical sciences, microbial strains characterization & mechanistics, QA/QC, GLP and laboratory accreditation. He co-authored 10+ scientific research articles, and presented 30+ lectures & posters at international conferences.
Live Q&A – Ask the speakers your questions 1:20 pm
day: Day One
Safety Bioanalytics in LHON Clinical Studies: Technical Challenges & Solutions & Outcomes 12:30 pm
• LHON disease and Gensight GS010 gene therapy & clinical trials (overall design & safety of bioanalytical assays) • Two examples of challenges faced regarding bioanalytical protocols being used: i) qPCR specificity for assessment of viral particles systemic biodissemination; ii) Impact of blood sampling and blood cells isolation on physiological state of PBMCs used for…Read more
day: Day One